Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYMN: Hyperthermia + Mitomycin vs BCG/Standard in Recurrent NMIBC
NCT01094964Phase 3Unknown
- Sponsor
- CRUK & UCL Cancer Trials Centre
- Start
- Oct 2009
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mitomycin c in Non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by CRUK & UCL Cancer Trials Centre. Primary endpoints: Disease-free survival time at 2 years and Complete response rate at 3 months. Status: unknown.
02
Drugs
mitomycin c
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT01094964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01094964.